Tema Etfs LLC Acquires New Shares in Olema Pharmaceuticals, Inc. $OLMA

Tema Etfs LLC bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 4th quarter, Holdings Channel.com reports. The firm bought 44,505 shares of the company’s stock, valued at approximately $1,113,000.

Several other institutional investors also recently bought and sold shares of OLMA. Nisa Investment Advisors LLC lifted its position in shares of Olema Pharmaceuticals by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after buying an additional 477 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after acquiring an additional 2,168 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Olema Pharmaceuticals by 0.4% during the 3rd quarter. Bank of America Corp DE now owns 802,304 shares of the company’s stock valued at $7,855,000 after acquiring an additional 2,802 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Olema Pharmaceuticals in the 3rd quarter valued at approximately $53,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Olema Pharmaceuticals by 46.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,442 shares of the company’s stock valued at $96,000 after acquiring an additional 7,146 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on OLMA. Piper Sandler began coverage on Olema Pharmaceuticals in a research report on Wednesday, January 7th. They set an “overweight” rating and a $40.00 target price for the company. The Goldman Sachs Group dropped their price target on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Thursday, January 22nd. Finally, Citigroup raised their target price on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $44.40.

Olema Pharmaceuticals Trading Down 0.4%

Olema Pharmaceuticals stock opened at $15.06 on Friday. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.95 and a current ratio of 9.95. The firm has a market capitalization of $1.31 billion, a PE ratio of -8.10 and a beta of 2.17. The business’s 50-day simple moving average is $20.67 and its 200-day simple moving average is $19.16.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Monday, March 16th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.01. Equities research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total value of $268,800.00. Following the completion of the sale, the director directly owned 727,770 shares of the company’s stock, valued at approximately $19,562,457.60. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shane William Charles Kovacs sold 100,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $28.73, for a total transaction of $2,873,000.00. Following the completion of the sale, the insider owned 139,727 shares in the company, valued at approximately $4,014,356.71. The trade was a 41.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 217,311 shares of company stock valued at $5,965,254 in the last three months. 16.36% of the stock is owned by corporate insiders.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.